Sökning: "Lewy Body Dementia"
Visar resultat 1 - 5 av 19 avhandlingar innehållade orden Lewy Body Dementia.
1. Living with Lewy body dementia. Treatment, survival & quality of life
Sammanfattning : Background: Patients with Lewy body dementias (LBD) have a complex clinical picture. With no prevention or cure, management focuses around symptomatic relief, however pharmacological and non-pharmacological options have been inadequately investigated. LÄS MER
2. Biochemical markers in dementia - Exploring Swedish registry data and the human proteome
Sammanfattning : Cerebrospinal fluid (CSF) biomarkers of neurodegenerative diseases have a wide scope of applications in diagnostics, prognosis assessment, disease staging, treatment evaluation and more. In this PhD project we aimed to expand the understanding of the properties of known CSF biomarkers of Alzheimer’s disease (AD) and other neurodegenerative diseases, including the most prevalent dementia disorders. LÄS MER
3. Dementia with Lewy bodies —an Investigation of Cause and Consequence
Sammanfattning : Dementia with Lewy bodies (DLB) is today considered to be the second most common primary neurodegenerative dementia after Alzheimer’s disease. However, the disease has only been a clearly defined entity for 13 years. LÄS MER
4. Neuropathological findings and staging in dementia
Sammanfattning : Dementia is a clinical syndrome with the development of impairment in multiple cognitive functions (including memory), severe enough to interfere with activities of daily living, as the main symptom. There are a large number of disorders that can lead to dementia, and neuropathological examination after death is necessary to determine the underlying cause with certainty. LÄS MER
5. Validation of brief cognitive tests in mild cognitive impairment, Alzheimer's disease and dementia with Lewy bodies
Sammanfattning : Background It is estimated that 34 million people suffer from dementia, costing society US$422 billion each year. Alzheimer’s disease (AD) is the most common dementia and the global prevalence is predicted to increase to over 100 million people by the year 2050, with the greatest increase in developing countries. LÄS MER